Language

Current Cancer Trials

Participate in One of These Clinical Trials

National Cancer Institute Trials:  

With a grant from the National Cancer Institute (NCI), more than 30 established, recognized clinical oncology programs have joined together to form the Northwest Community Oncology Research Program (NW NCORP).

MultiCare Health System is amongst a network of hospitals, clinics, physicians, and researchers working together to provide cancer education and access to new and unique cancer clinical trials to the men, women, and children in communities across Washington, Utah and Alaska.

Learn more about Clinical Trials available at MultiCare


Cancer Clinical Trials offered by MultiCare Health System

Brain


Breast - Triple Negative

B-59/GBC 96

A Randomized, Double-Blind, Phase III Clinical Trial of Neoadjuvant Chemotherapy with Atezolizumab or Placebo in Patients with Triple-Negative Breast Cancer Followed by Adjuvant Continuation of Atezolizumab or Placebo

Protocol Summary

NRG BR003

A randomized Phase III trial of adjuvant therapy comparing Doxorubicin plus Cyclophosphamide followed by weekly Paclitaxel with or without Carboplatin for node-positive or high-risk node-negative triple-negative invasive breast cancer

Protocol Summary

EA1131

A randomized Phase III post-operative trial of platinum-based chemotherapy vs. observation in patients with residual triple-negative breast cancer following neoadjuvant chemotherapy

Protocol Summary

S1418/BR006

A randomized Phase III trial to evaluate the efficacy and safety of MK-3475 as adjuvant therapy for triple receptor-negative breast cancer with ≥1 cm residual invasive cancer or positive lymph nodes after neoadjuvant chemotherapy

Protocol Summary

Breast - Node Positive

A011202

A randomized Phase III trial comparing Axillary Lymph Node Dissection to Axillary Radiation in breast cancer patients (cT1-3 N1) who have positive Sentinel Lymph Node Disease after neoadjuvant chemotherapy

Protocol Summary

NSABP B51

Randomized Phase III clinical trial evaluating post-mastectomy chest wall and regional nodal XRT and post-lumpectomy regional nodal XRT in patients with positive axillary nodes before neoadjuvant chemotherapy who convert to pathologically negative axillary nodes after neoadjuvant chemotherapy

Protocol Summary

A011502

A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for HER2 Negative Breast Cancer: The ABC Trial

Protocol Summary

Breast - HER2 Positive Metastatic

DS8201-A-U301

A Phase 3, multicenter, randomized, open-label, active-controlled study of DS-8201a, an anti-HER2-antibody drug conjugate, versus treatment of investigator’s choice for HER2-positive, unresectable and/or metastatic breast cancer subjects pretreated with prior standard of care HER2 therapies, including T-DM1

Protocol Summary

DS8201-A-U302

A Phase 3, multicenter, randomized, open-label, active-controlled study of DS-8201a, an anti-HER2-antibody drug conjugate, versus ado-trastuzumab emtansine (T-DM1) for HER2-positive, unresectable and/or metastatic breast cancer subjects previously treated with trastuzumab and taxane

Protocol Summary

Breast - Other

A011401

(BWEL) Randomized Phase III trial evaluating the role of weight loss in adjuvant treatment of overweight and obese women with early breast cancer

Protocol Summary

NRG‐CC004

Phase II Double Blind Dose Finding Trial of Bupropion Versus Placebo for Sexual Desire in Women with Breast or Gynecologic Cancer

Protocol Summary


Pancreas

8951-CL-5201

A Phase 2, Open-Label, Randomized Study to Assess the Antitumor Activity and Safety of Zolbetuximab (IMAB362) in Combination With Nab-Paclitaxel and Gemcitabine (Nab-P + GEM) as First Line Treatment in Subjects With Claudin 18.2 (CLDN18.2) Positive, Metastatic Pancreatic Adenocarcinoma

Protocol Summary


Gastrointestinal - Colon

S0820

A Double Blind Placebo‐Controlled Trial of Eflornithine and Sulindac to Prevent Recurrence of High Risk Adenomas and Second Primary Colorectal Cancers in Patients with Stage 0‐III Colon or Rectal Cancer, Phase III‐ Preventing Adenomas of the Colon with Eflornithine and Sulindac (PACES)

Protocol Summary

Gastrointestinal - Metastatic Pancreas

8951-CL-5201

A Phase 2, Open-Label, Randomized Study to Assess the Antitumor Activity and Safety of Zolbetuximab (IMAB362) in Combination With Nab-Paclitaxel and Gemcitabine (Nab-P + GEM) as First Line Treatment in Subjects With Claudin 18.2 (CLDN18.2) Positive, Metastatic Pancreatic Adenocarcinoma

Protocol Summary

Gastrointestinal - Rectal 

NRG-GI002

Phase II Clinical Trial Platform of Sensitization Utilizing Total Neoadjuvant Therapy (TNT) in Rectal Cancer

Protocol Summary


Genitourinary - Prostate 

TRITON3 CO-338-063

A Multicenter, Randomized, Open-label Phase 3 Study of Rucaparib versus Physician’s Choice of Therapy for Patients with Metastatic Castration-resistant Prostate Cancer Associated with Homologous Recombination Deficiency

Protocol Summary

NRG‐GU002

A Phase II‐III Trial of Adjuvant Radiotherapy and Androgen Deprivation Following Radical Prostatectomy With or Without Adjuvant Docetaxel

Protocol Summary

Genitourinary - Bladder

A031501

A Phase 3 Randomized Adjuvant Study of MK-3475 (Pembrolizumab) in Muscle Invasive and Locally Advanced Urothelial Carcinoma (AMBASSADOR) Versus Observation

Protocol Summary

Gynecologic - Ovarian

NRG‐GY009

A Randomized, Phase II/III Study of Pegylated Liposomal Doxorubicin and CTEP‐Supplied Atezolizumab Versus Pegylated Liposomal Doxorubicin/Bevacizumab and CTEP‐Supplied Atezolizumab Versus Pegylated Liposomal Doxorubicin/Bevacizumab in Platinum Resistant Ovarian Cancer

Protocol Summary

Gynecologic - Uterine or Vaginal

NRG‐GY006

A Randomized Phase II Trial of Radiation Therapy and Cisplatin Alone or in Combination with Intravenous Triapine in Women with Newly Diagnosed Bulky Stage IB2, Stage II, IIIB, or IVA Cancer of the Uterine Cervix or Stage II‐IVA Vaginal Cancer

Protocol Summary

Gynecologic - Other

NRG‐CC004

Phase II Double Blind Dose Finding Trial of Bupropion Versus Placebo for Sexual Desire in Women with Breast or Gynecologic Cancer

Protocol Summary


Head and Neck

NRG HN004

Randomized Phase II/III Trial of Radiotherapy With Concurrent MEDI4736 (Durvalumab) vs. Radiotherapy With Concurrent Cetuximab in Patients With Locoregionally Advanced Head and Neck Cancer With a Contraindication to Cisplatin

Protocol Summary

AG013-ODOM-201A (ORAGENICS)

A Phase II, multicenter, randomized, double-blind, placebo-controlled study to assess the safety and efficacy of topically applied AG013 for the attenuation of oral mucositis in subjects with cancers of the head and neck receiving concomitant chemoradiation therapy

Protocol Summary


Lung

HS-10296-12-01 (Hansoh)

A Phase 1/2, open-label, multicenter study to evaluate safety, tolerability, pharmacokinetics, and efficacy of oral once-daily administration of HS-10296 in patients with locally advanced or metastatic non-small cell lung cancer who have progressed following prior therapy with an epidermal growth factor receptor Tyrosine Kinase inhibitor agent

Protocol Summary

A081105-EGFR

Randomized, double-blind, placebo-controlled study of Erlotinib or placebo in patients with completely resected epidermal growth factor receptor (EGFR) mutant non-small cell lung cancer.

Protocol Summary

A151216

Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)

Protocol Summary


Leukemia-Chronic

EA9161

A Randomized Phase III Study of the Addition of Venetoclax to Ibrutinib and Obinutuzumab Versus Ibrutinib and Obinutuzumab in Untreated Younger Patients With Chronic Lymphocytic Leukemia (CLL)

Protocol Summary

A041702

A Randomized Phase III Study of Ibrutinib Plus Obinutuzumab Versus Ibrutinib Plus Venetoclax and Obinutuzumab in Untreated Older Patients (>/= 70 Years of Age) With Chronic Lymphocytic Leukemia (CLL)

Protocol Summary


Melanoma

EA6134

DREAMseq (Doublet, Randomized Evaluation in Advanced Melanoma Sequencing) A Phase III Trial

Protocol Summary


Other (Tumor Profiling, Registries, etc.)

STR-001-001 

An Observational Study profiling Biospecimens from Cancer Patients to Screen for Molecular Alterations

DCP-001

Use of a Clinical Trial Screening Tool to Address Cancer Health Disparities in the NCI Community Oncology Research Program (NCORP)

S1415CD

A Pragmatic Trial to Evaluate a Guideline Based Colony Stimulating Factor Standing Order Intervention and to Determine the Effectiveness of Colony Stimulating Factor Use as Prophylaxis for Patients Receiving Chemotherapy with Intermediate Risk for Febrile Neutropenia — Trial Assessing CSF Prescribing Effectiveness and Risk (Tracer).

S1609

DART: Dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors

EAY131

Molecular Analysis for Therapy Choice (MATCH)

PCYC-1134M

A disease registry for patients with Chronic Lymphocytic Leukemia.

PRECISION MED 6504

Collection of blood, urine, and tissue samples from patients with malignant tumors

AFT-28

Direct Oral Anticoagulants (DOACS) Versus LMWH +/- Warfarin for VTE in Cancer: A Randomized Effectiveness Trial (CANVAS TRIAL). Arm 1

EAQ171CD

Implementing a Virtual Tobacco Treatment in Community Oncology Practices: "Smoke Free Support Study 2.0"

A231602CD

Assessing Financial Difficulty in Patients With Blood Cancers


Pediatric/Adolescent and Young Adult Trials

AALL1131

A Phase III Randomized Trial for Newly Diagnosed High Risk B-Lymphoblastic Leukemia (B-ALL) Including a Stratum Evaluating Dasatinib (NSC#732517) in Patients With Ph-Like Tyrosine Kinase Inhibitor (TKI) Sensitive Mutations

AAML1331

A Phase III Study for Patients With Newly Diagnosed Acute Promyelocytic Leukemia (APL) Using Arsenic Trioxide and All-Trans Retinoic Acid

ACNS0831

Phase III Randomized Trial of Post-Radiation Chemotherapy in Patients With Newly Diagnosed Ependymoma Ages 1 to 21 Years

ACNS1422

Phase 2 Study of Reduced Therapy for Newly Diagnosed Average-Risk WNT-Driven Medulloblastoma Patients

ANHL12P1

A Randomized Phase 2 Trial of Brentuximab Vedotin (SGN35, NSC# 749710), or Crizotinib (NSC#749005, Commercially Labeled) in Combination With Chemotherapy for Newly Diagnosed Patients With Anaplastic Large Cell Lymphoma (ALCL)

AGCT1531

A Phase 3 Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients with Germ Cell Tumors

ARST1431

A Randomized Phase 3 Study of Vincristine, Dactinomycin, Cyclophosphamide (VAC) Alternating With Vincristine and Irinotecan (VI) Versus VAC/VI Plus Temsirolimus (TORI, Torisel, NSC# 683864) in Patients With Intermediate Risk (IR) Rhabdomyosarcoma (RMS)